Component information
No US or EU label exists for this exact combination, so information is shown for each component.
- fluid extract of pumpkin seeds no separate page
- fluid extract of worm seeds no separate page
- senna leaves no separate page
Use: to raise plasma pH in adult and pediatric patients with clinically significant metabolic acidosis. US FDA label
Kidney dosing: Sodium bicarbonate (single-agent)Show full dosing details
- CrCl ≥60 mL/min
- IV for metabolic acidosis (adults and children 2 years and older): 2 to 5 mEq/kg over 4 to 8 hours, by bicarbonate, total CO2, pH and clinical state (label). Treat the cause.
- CrCl 30–59 mL/min
- No kidney dose change in the label. Kidney disease and anuria increase sensitivity to the sodium load: watch for fluid overload, edema and blood pressure, and adjust other sodium sources (label 5.1). Monitor bicarbonate, sodium and potassium; avoid overshoot alkalosis. Oral tablets for CKD metabolic acidosis: consider treatment to keep serum bicarbonate from falling below 18 mmol/L, and do not overshoot the upper limit of normal; watch blood pressure, potassium and fluid status (KDIGO 2024 PP 3.10.1, 3.10.2). Each 650 mg tablet supplies about 7.7 mEq of sodium and bicarbonate (325 mg about 3.9 mEq); 8.4% solution is 1 mEq/mL (84 mg per mEq; label 3: 12.6 mg/mL = 0.150 mEq/mL). Oral doses are not in the label.
- CrCl 15–29 mL/min
- No kidney dose change in the label. Kidney disease and anuria increase sensitivity to the sodium load: watch for fluid overload, edema and blood pressure, and adjust other sodium sources (label 5.1). Monitor bicarbonate, sodium and potassium; avoid overshoot alkalosis. Oral tablets for CKD metabolic acidosis: consider treatment to keep serum bicarbonate from falling below 18 mmol/L, and do not overshoot the upper limit of normal; watch blood pressure, potassium and fluid status (KDIGO 2024 PP 3.10.1, 3.10.2). Each 650 mg tablet supplies about 7.7 mEq of sodium and bicarbonate (325 mg about 3.9 mEq); 8.4% solution is 1 mEq/mL (84 mg per mEq; label 3: 12.6 mg/mL = 0.150 mEq/mL). Oral doses are not in the label.
- CrCl <15 mL/min (not on dialysis)
- No kidney dose change in the label. Kidney disease and anuria increase sensitivity to the sodium load: watch for fluid overload, edema and blood pressure, and adjust other sodium sources (label 5.1). Monitor bicarbonate, sodium and potassium; avoid overshoot alkalosis. Oral tablets for CKD metabolic acidosis: consider treatment to keep serum bicarbonate from falling below 18 mmol/L, and do not overshoot the upper limit of normal; watch blood pressure, potassium and fluid status (KDIGO 2024 PP 3.10.1, 3.10.2). Each 650 mg tablet supplies about 7.7 mEq of sodium and bicarbonate (325 mg about 3.9 mEq); 8.4% solution is 1 mEq/mL (84 mg per mEq; label 3: 12.6 mg/mL = 0.150 mEq/mL). Oral doses are not in the label.
- Hemodialysis (intermittent)
- No dose change; anuria raises the risk of fluid overload from the sodium load (label 5.1). Dialysate bicarbonate also corrects acidosis; coordinate with the dialysis prescription (clinical judgment).
- Peritoneal dialysis
- No dose change; watch sodium load and fluid status (label 5.1).
- CRRT
- No data in label. CRRT fluids are usually bicarbonate-buffered; added IV bicarbonate is a specialist decision guided by blood gases.
- Dialyzable? Bicarbonate crosses dialysis membranes in both directions according to the dialysate bicarbonate concentration (physiology; not stated in label).
- Monitoring Blood gases or serum bicarbonate, sodium, potassium (hypokalemia as acidosis corrects), fluid status, blood pressure, edema. Extravasation site (hypertonic solutions).
From the Sodium bicarbonate monograph (renalcarematters.com, reviewed).
- sodium potassium tartrate no separate page
Note: Fixed-dose combinations may not allow the dose changes advised for each component; check the strength and use the single agents if a component needs adjusting.
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney dosing for each component (single-agent) is shown under Component information.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosage forms
Philippines
- Syrup: 500 mg/160 mg/61 mcL/61 mcL/50 mg per 5 mL, 500 mg/160 mg/61 uL/61 uL/50 mg per 5 mL
Registered products in the Philippines
2 products registered with the Food and Drug Administration (FDA) Philippines list Fluid extract of pumpkin seeds + Fluid extract of worm seeds + Senna leaves + Sodium bicarbonate + Sodium potassium tartrate as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
Watsonal CastoriaSenna Leaves (Cassia angustifolia) + Sodium Potassium Tartrate (Rochelle Salt) + Fluid Extract of Worm Seeds (Chenopodium ambrosioides) + Fluid Extract of Pumpkin Seeds (Cucurbita pepo Linne) + Sodium Bicarbonate | 500 mg/160 mg/61 uL/61 uL/50 mg per 5 mL SyrupFlint Clear Glass Bottle x 30 mL (Box of 1's); Amber Boston Glass Bottle x 60 mL (Box of 1's) | HR | Hizon Laboratories, Inc.Philippines | Trader: Boie Incorporated | DRHR-1922 | Aug 30, 2029 | |
Watsonal Castoria Nf"Senna Leaves (Cassia angustifolia) + Sodium Potassium Tartrate + Fluid Extract of Worm Seeds (Chenopodium ambrosioides) + Fluid Extract of Pumpkin Seeds (Cucurbita pepo Linne) + Sodium Bicarbonate " | 500 mg/160 mg/61 mcL/61 mcL/50 mg per 5 mL SyrupAmber PET Bottle x 60 mL (Box of 1's) | Rx | Hizon Laboratories, Inc.Philippines | Trader: Boie Incorporated | DRHR-1923 | Aug 30, 2031 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .